广州医药 ›› 2024, Vol. 55 ›› Issue (12): 1490-1494.DOI: 10.20223/j.cnki.1000-8535.2024.12.016

• 论著 • 上一篇    下一篇

血清胱抑素C联合β2-微球蛋白检测在糖尿病肾病早期诊断中的应用价值

陈丽娜, 陈慧明, 谢春红   

  1. 厦门医学院附属第二医院检验科(福建厦门 361021)
  • 收稿日期:2024-03-29 出版日期:2024-12-20 发布日期:2025-01-08

Application value of serum cystatin C combined with β2-microglobulin in the early diagnosis of diabetic nephropathy

CHEN Lina, CHEN Huiming, XIE Chunhong   

  1. Laboratory Department, the Second Affiliated Hospital of Xiamen Medical College, Xiamen 361021, China
  • Received:2024-03-29 Online:2024-12-20 Published:2025-01-08

摘要: 目的 探讨血清胱抑素C(Cys-C)联合β2-微球蛋白(β2-MG)早期诊断糖尿病肾病的应用价值。方法 选择2021年4月—2023年4月医院接收的100例糖尿病患者为对象,根据其有无合并肾脏疾病,将其分为糖尿病组及糖尿病肾病组,各50例,同比例选取同期到我院体检的健康人群50名进行对照研究,检测比较其Cys-C及β2-MG水平,对比其Cys-C阳性率、β2-MG阳性率及联合检测阳性率,并对比不同疾病分期糖尿病肾病患者的Cys-C、β2-MG水平。结果 糖尿病肾病患者Cys-C、β2-MG水平高于糖尿病患者与健康者(P<0.05)。糖尿病患者Cys-C、β2-MG水平高于健康者(P<0.05)。糖尿病肾病患者Cys-C阳性率64.00%、β2-MG阳性率72.00%、Cys-C+β2-MG联合检测阳性率96.00%高于糖尿病6.00%、10.00%、12.00%及健康者0.00%、0.00%、0.00%(P<0.05);糖尿病Cys-C+β2-MG联合检测阳性率12.00%高于健康者0.00%(P<0.05);糖尿病肾病中Cys-C+β2-MG联合检测阳性率96.00%高于CysC 64.00%、β2-MG 72.00%(P<0.05)。糖尿病肾病不同分期患者Cys-C、β2-MG水平比较,Ⅳ期>Ⅲ期>Ⅰ~Ⅱ期(P<0.05)。结论 糖尿病肾病患者Cys-C、β2-MG水平明显升高,Cys-C、β2-MG联合诊断更具有优势,而且肾损害越严重,Cys-C、β2-MG异常程度越高,作为临床诊治的参考依据的价值较高。

关键词: 糖尿病肾病, 胱抑素C, β2-微球蛋白, 早期诊断

Abstract: Objective To investigate the application value of serum cystatin C(Cys-C)combined with β2-microglobulin(β2-MG)in the early diagnosis of diabetic nephropathy.Methods A total of 100 diabetic patients admitted to our hospital from April 2021 to April 2023 were selected as subjects,and divided into diabetes group and diabetic nephropathy group according to whether they have renal diseases or not,with 50 cases in each group.Then,50 healthy people who came to our hospital for physical examination in the same period were selected for comparative study,and their Cys-C and β2-MG levels were detected and compared,and their Cys-C positive rate,β2-MG positive rate and combined detection positive rate were compared.Results The levels of Cys-C and β2-MG in patients with diabetic nephropathy were higher than those in patients with diabetes and healthy controls(P<0.05).The levels of Cys-C and β2-MG in diabetic patients were higher than those in healthy controls(P<0.05).The positive rates of Cys-C(64.00%),β2-MG(72.00%)and Cys-C+β2-MG(96.00%)in patients with diabetic nephropathy were higher than those in patients with diabetes(6.00%,10.00%,12.00%)and healthy subjects(0.00%,0.00%,0.00%)(P<0.05).The positive rate of combined detection of Cys-C and β2-MG in diabetic patients(12.00%)was higher than that in healthy subjects(0.00%)(P<0.05).The positive rate of Cys-C combined with β2-MG in diabetic nephropathy was 96.00%,which was higher than that of Cys-C 64.00% and β2-MG 72.00%(P<0.05).The levels of Cys-C and β2-MG in patients with stage Ⅳ diabetic nephropathy were higher than those in patients with stage Ⅲ and Ⅰ-Ⅱ diabetic nephropathy(P<0.05).The levels of Cys-C and β2-MG in stage Ⅲ patients were higher than those in stage Ⅰ-Ⅱ patients(P<0.05).Conclusions The levels of Cys-C and β2-MG are significantly increased in patients with diabetic nephropathy,and the combination of Cys-C and β2-MG has more advantages.The greater serious renal damage,the greater abnormal degree of Cys-C and β2-MG,which has a higher value as a reference for clinical diagnosis and treatment.

Key words: diabetic nephropathy, Cystatin C, β2-microglobulin, early diagnosis